Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorKafrelsheikh University
About this trial
This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).
Eligibility criteria
Qualifiers
Age ≥ 18 years old.
Both sexes.
Patients with a history of prosthetic heart valves.
Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.
Disqualifiers
Hemodynamic instability.
Use of a circulatory auxiliary circulation device.
Severe hepatic [alanine aminotransferase (ALT) >120 U/L] and renal insufficiency [estimated glomerular filtration rate (eGFR) <30 mL/min].
Blood pressure <100/60 mmHg.
Trial design
Treatments tested in this trial
- Sacubitril/Valsartan
- Conventional anti-heart failure therapy
Treatment groups
220 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov